MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
Holders of 5% or more of INKT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of MiNK Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of MiNK Therapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
6 Schedule 13D and 13G filings on MiNK Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 22, 2024 | GKCC, LLC | 13GOld format | – | New | – | SEC |
| Feb 14, 2024 | Armen Garo H | 13DOld format | – | – | – | SEC |
| May 26, 20235:03 PM ET | Agenus Inc | 13D/AOld format | – | – | – | SEC |
| May 3, 20235:23 PM ET | Agenus Inc | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Armen Garo H | 13GOld format | – | New | – | SEC |
| Oct 28, 20214:30 PM ET | Agenus Inc | 13DOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell MiNK Therapeutics, Inc. shares.
No Form 144 notices for MiNK Therapeutics, Inc. are on file.